Indication
Carcinoma
10 clinical trials
14 products
4 drugs
Product
IBI133Clinical trial
A Multicentre, Open-label, Phase 1/2 Study of IBI133 in Subjects With Unresectable, Locally Advanced or Metastatic Solid TumoursStatus: Recruiting, Estimated PCD: 2025-12-30
Clinical trial
A Phase 1a/b, Multicenter, Open-label, First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid TumorsStatus: Recruiting, Estimated PCD: 2024-05-31
Product
IBI343Clinical trial
Phase 1, Open-Label, Safety Study of Escalating Doses of Ex Vivo Expanded, Autologous Natural Killer Cells in Patients With Pathologically Confirmed Cancer Refractory to Conventional TherapyStatus: Completed, Estimated PCD: 2023-02-17
Product
SNK01Product
AvelumabProduct
PembrolizumabProduct
IBI354Clinical trial
A Phase 1/2, Multicenter, Open-label Study of IBI354 in Subjects With Locally Advanced Unresectable or Metastatic Solid TumorsStatus: Not yet recruiting, Estimated PCD: 2024-10-15
Clinical trial
A Phase Ia/Ib Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SG1906 in Patients With CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Solid Tumors.Status: Recruiting, Estimated PCD: 2025-02-28
Product
SG1906Clinical trial
Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung CancerStatus: Recruiting, Estimated PCD: 2033-12-30
Product
Montanide ISA-51 VGProduct
H1299 Cell LysatesDrug
N-803Clinical trial
Phase II Trial of Immunotherapy in Patients With Carcinomas Arising From the Renal MedullaStatus: Recruiting, Estimated PCD: 2027-07-16
Drug
T-VECProduct
RelatlimabClinical trial
Combination of MEK Inhibitor Binimetinib and CDK4/6 Inhibitor Palbociclib in KRAS and NRAS Mutant Metastatic Colorectal CancersStatus: Active (not recruiting), Estimated PCD: 2021-08-23
Product
BinimetinibProduct
PalbociclibClinical trial
Phase II Study of AK104 (Cadonilimab) for Recurrent Small Cell Neuroendocrine Carcinomas of the CervixStatus: Active (not recruiting), Estimated PCD: 2025-08-01
Drug
CadonilimabClinical trial
Phase I Multi-Center Study of Hypofractionated Radiotherapy in Combination With Durvalumab and Tremelimumab in Patients With Recurrent/Metastatic Advanced Cervical, Vaginal, or Vulvar CancerStatus: Completed, Estimated PCD: 2023-08-11
Drug
AN0025Product
Tremelimumab